Our findings in CXCR2 LOF mice are consistent with previous reports in patients with WHIM syndrome indicating that CXCR4 antagonist treatment results in clinically significant improvements in peripheral blood neutrophil levels and reductions in infection rates (64). The gene discussed is CXCR4; the disease is infection.